Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendous...
Saved in:
Main Authors: | Gopalakrishnan S, Tan D |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2021) -
HOW I TREAT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS?
by: María-Victoria Mateos
Published: (2021) -
INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
by: Vasile Musteata, et al.
Published: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
by: Liu YC, et al.
Published: (2014) -
CASE REPORT: COEXISTENCE OF CELIAC DISEASE AND MULTIPLE MYELOMA
by: Filiz YAVASOGLU, et al.
Published: (2021)